Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.
Related posts:
- Launches collaborative program with industry and researchers to spur therapeutic development The National Institutes of Health today unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients. NIH’s new National Center for Advancing Translational Sciences (NCATS) has partnered initially with Pfizer, AstraZeneca, and Eli Lilly and Company which have agreed to make dozens […]...
- Christopher P. Austin named National Center for Advancing Translational Sciences director Christopher P. Austin, M.D., will serve as director of the NIH’s newest center, the National Center for Advancing Translational Sciences (NCATS). National Institutes of Health Director Francis S. Collins, M.D., Ph.D., made the announcement at the inaugural meetings of the NCATS Advisory Council and Cures Acceleration Network (CAN) Review Board. Austin will succeed NCATS Acting […]...
- Rare Disease Day at NIH raises awareness and highlights cutting-edge research The National Institutes of Health will celebrate the Fifth Annual Rare Disease Day February 29 with a day-long celebration co-sponsored by the Office of Rare Diseases Research-National Center for Accelerating Translational Research, and the NIH Clinical Center....
- US Tox21 to begin screening 10,000 chemicals A high-speed robotic screening system, aimed at protecting human health by improving how chemicals are tested in the United States, begins today to test 10,000 compounds for potential toxicity. Testing this 10,000 compound library begins a new phase of an ongoing collaboration between the National Institutes of Health, the U.S. Environmental Protection Agency, and the […]...
- National Center for Advancing Translational Sciences In a move to re-engineer the process of translating scientific discoveries into new drugs, diagnostics, and devices, the National Institutes of Health has established the National Center for Advancing Translational Sciences (NCATS)....
- Bladder tests before urinary incontinence surgery in women may be unnecessary The National Institutes of Health today unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients. NIH’s new National Center for Advancing Translational Sciences (NCATS) has partnered initially with Pfizer, AstraZeneca, and Eli Lilly and Company which have agreed to make dozens […]...
- Clinical trial stopped on combination cholesterol treatment The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular […]...
- Industry announce new translational science initiative National Institutes of Health press conference with U.S. Department of Health and Human Services Secretary Kathleen Sebelius, NIH Director Francis S. Collins, M.D., Ph.D., and pharmaceutical companies to announce a new translational science initiative by the National Center for Advancing Translational Sciences....
- Medicare Card, NHGRI to develop revolutionary technologies for exploring genome function The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, has awarded 10 grants, totaling $10.5 million, to develop revolutionary technologies that will help researchers identify millions of genomic elements that play a role in determining what genes are expressed and at what levels in different cells. These multi-year grants are […]...
- Sequencing program focus on inherited diseases, medical applications A new funding plan by the National Human Genome Research Institute (NHGRI) sharpens the focus of its flagship Genome Sequencing Program on medical applications. In addition to continuing on-going studies, the four-year, $416 million plan launches new efforts to find causes of rare inherited diseases and accelerate the use of genome sequence information in the […]...
- Chikungunya vaccine trial begins to enroll participants An experimental vaccine to prevent chikungunya fever, a viral disease spread by certain species of mosquitoes, is being tested in a clinical trial conducted by National Institute of Allergy and Infectious Diseases (NIAID) scientists at the National Institutes of Health....
- NHGRI collaborates with Smithsonian to produce new genome exhibit To celebrate the 10th anniversary of the completion of the first complete human genome sequence — the genetic blueprint of the human body — the Smithsonian Institution will open a high-tech, high-intensity exhibit in 2013. The exhibit is a collaboration of the Smithsonian’s National Museum of Natural History (NMNH) and the National Human Genome Research […]...
- Medicare Card News: NIH Researchers Explore How Healthy, Young Adults View the Role Genetics Plays in Improving Health Most healthy young adults place greater emphasis on health habits than on genetic risk factors when considering what causes common diseases, a research team from the National Human Genome Research Institute (NHGRI) and the Henry Ford Health System in Detroit has found. The study, based on a survey of 25- to-45-year-olds, was released June 8, […]...
- Adverse Cardiovascular Events Reported in Testosterone Trial in Older Men A clinical trial of testosterone treatment in older men, reported June 30 online in the New England Journal of Medicine, has found a higher rate of adverse cardiovascular events, such as heart attacks and elevated blood pressure, in a group of older men receiving testosterone gel compared to those receiving placebo. Due to these events, […]...
- Medicare Card, National Institutes of Health launches summer institute on mHealth The National Institutes of Health today announced the creation of the first NIH Health, or mobile health, Summer Institute. Scheduled for the summer of 2011, this week-long workshop will bring together leaders in mobile health technologies, behavioral science researchers, federal health officials and members of the medical community to provide early career investigators with an […]...